局灶隐匿性胎盘植入谱系疾病:孕产妇发病的隐匿来源
本研究回顾性比较2018至2022年一家三级医疗中心经病理确诊的74例胎盘植入谱系疾病,其中局灶隐匿性43例、前置胎盘相关31例。局灶隐匿性组再次手术率更高(30.2% vs 6.5%,P=.01),其余发病结局无显著差异,作者认为发病结局无差异可能与产前未检出局灶隐匿性植入有关,值得进一步研究。
要点
- 局灶隐匿性胎盘植入谱系疾病产前仅1例确诊,前置胎盘相关组产前确诊29例。
- 局灶隐匿性组再次手术或重返手术室发生率30.2% vs 前置胎盘相关组6.5%(P=.01)。
- 两组出血、输血、ICU入住及复合发病结局无显著差异,但局灶隐匿性组有发病更高的非显著趋势。
核心结论
- 局灶隐匿性胎盘植入谱系疾病可识别危险因素少于前置胎盘相关胎盘植入谱系疾病,但可能与体外受精妊娠相关。
- 局灶隐匿性组再次手术发生率高于前置胎盘相关组,其他发病结局未见其他统计学显著差异。
- 发病结局无差异可能归因于局灶隐匿性植入缺乏产前检出,值得进一步研究。
研究设计与样本
- 2018至2022年在一家三级医疗中心开展的回顾性研究,纳入全部经病理确诊的胎盘植入谱系疾病病例。
- 共74例,其中局灶隐匿性胎盘植入谱系疾病43例、前置胎盘相关胎盘植入谱系疾病31例。
- 比较基线特征、手术与产科发病结局及后续妊娠结局,采用Kruskal-Wallis或卡方检验,P<.05为显著。
主要发现
- 局灶隐匿性组25.6%行子宫切除,前置胎盘相关组100%行子宫切除。
- 局灶隐匿性组产前确诊1例,前置胎盘相关组产前确诊29例。
- 平均产妇年龄33.0 vs 33.1岁、体重指数及既往刮宫史比例(16.3% vs 25.8%)两组无差异。
- 局灶隐匿性组平均产次较低(1.5 vs 3.6次妊娠)、分娩孕周较高(36.1 vs 33.9周),既往剖宫产比例较低(12/43,27.9% vs 30/31,96.8%)。
- 局灶隐匿性组既往剖宫产次数较少(均值0.5 vs 2.3)、体外受精比例较高(20.9% vs 3.2%),前壁胎盘着床较少。
关键数值与推荐
- 产后出血率71.0% vs 67.4%,平均失血量2099 mL(范围500-9516 mL)vs 2119 mL(范围350-12,220 mL),平均输注红细胞单位1.4 vs 1.7,大量输血率9.3% vs 3.2%,ICU入住率11.6% vs 6.5%,均无显著差异。
- 再次手术或重返手术室发生率30.2% vs 6.5%(P=.01)。
- 复合结局:出血相关发病77.4% vs 74.4%,任何孕产妇发病83.9% vs 76.7%,严重孕产妇发病64.5% vs 65.1%,两组无显著差异。
- 9例局灶隐匿性患者有后续妊娠,其中3例复发胎盘植入谱系疾病。
局限性
- 作者认为发病结局无差异可能归因于局灶隐匿性植入缺乏产前检出,值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Focal-occult placenta accreta spectrum is known to cause adverse obstetrical morbidity outcomes, however, direct comparisons with previa-associated placenta accreta spectrum morbidity are lacking. OBJECTIVE: We sought to compare the baseline characteristics, surgical and obstetrical morbidity, and subsequent pregnancy outcomes of patients with focal-occult placenta accreta spectrum with those of patients with previa-associated accreta. STUDY DESIGN: A retrospective review was conducted of all pathologically confirmed placenta accreta spectrum cases from 2018 to 2022 at a tertiary care center. The baseline characteristics, surgical, obstetrical, and subsequent pregnancy outcomes were recorded. Cases of focal-occult placenta accreta spectrum was compared with cases of previa-associated placenta accreta spectrum across a range of morbidity characteristics including hemorrhagic factors, interventions, postdelivery reoperations, infections, and intensive care unit admission. Statistical comparison was performed using Kruskal-Wallis or chi-square tests, and a P value of <.05 was considered significant. RESULTS: A total of 74 cases were identified with 43 focal-occult and 31 previa-associated placenta accreta spectrum cases. Of those, 25.6% of the patients with focal-occult placenta accreta spectrum and 100% of the patients with previa-associated placenta accreta spectrum underwent a hysterectomy. One case of focal-occult placenta accreta spectrum and 29 cases of previa-associated placenta accreta spectrum were diagnosed antenatally. Patients with focal-occult placenta accreta spectrum did not differ from those with previa-associated placenta accreta spectrum in mean maternal age (33.0 vs 33.1 years), body mass index, or the incidence of previous dilation and curettage procedures (16.3% vs 25.8%). Patients with focal-occult placenta accreta spectrum were significantly more likely to have a lower mean parity (1.5 vs 3.6 gestations), higher gestational age at delivery (36.1 vs 33.9 weeks' gestation), and were less likely to have had a previous cesarean delivery (12/43, 27.9% vs 30/31, 96.8%). In addition, patients with focal-occult placenta accreta spectrum had less previous cesarean deliveries (mean, 0.5 vs 2.3), were more likely to have undergone in vitro fertilization (20.9% vs 3.2%), and less likely to have anterior placentation. When contrasting the clinical outcomes of patients with focal-occult placenta accreta spectrum with those with previa-associated placenta accreta spectrum, the postpartum hemorrhage rates (71.0% vs 67.4%), mean quantitative blood loss (2099 mL; range, 500-9516 mL vs 2119 mL; range 350-12,220 mL), mean units of red blood cells transfused (1.4 vs 1.7), massive transfusion rate (9.3% vs 3.2%), and intensive care unit admission rates (11.6% vs 6.5%) were not significantly different, but there was a nonsignificant trend toward higher morbidity among patients with focal-occult accreta. Patients with focal-occult accreta had a higher incidence of reoperations or return to the operating room (30.2 vs 6.5%; P=.01). When comparing focal-occult with previa-associated placenta accreta spectrum, the composite outcomes, including hemorrhagic morbidity (77.4% vs 74.4%), any maternal morbidity (83.9% vs 76.7%), and severe maternal morbidity (64.5% vs 65.1%), were not significantly different between the groups. Nine focal-occult placenta accreta spectrum patients had a subsequent pregnancy, and 3 of those had recurrent placenta accreta spectrum. CONCLUSION: Focal-occult placenta accreta spectrum presents with fewer identifiable risk factors than placenta previa-associated placenta accreta spectrum but may be associated with an in vitro fertilization pregnancy. Patients with focal-occult placenta accreta spectrum was observed to have a higher incidence of reoperation when compared with patients previa-associated placenta accreta spectrum, and no other statistically significant differences in morbidity outcomes were observed. The absence of differences in morbidity outcomes may be attributable to a lack of antenatal detection of focal-occult accreta and merits further investigation.
引用
- Larish A, Horst K, Brunton J, et al. Focal-occult placenta accreta: a clandestine source of maternal morbidity. Am J Obstet Gynecol MFM. 2023. PMID: 36934974. doi:10.1016/j.ajogmf.2023.100924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。